Exelixis Cut Guidance by $50M. Its Free Cash Flow Grew 60%.

The market heard a $50 million guidance cut. The numbers tell a different story.

Exelixis lowered and narrowed its 2026 net product revenue guidance after its second-quarter earnings on August 5, trimming the midpoint from $2.375 billion to $2.325 billion. Management attributed the shift to slower-than-expected adoption of its flagship cabozantinib drug in neuroendocrine tumors - a slow-growing cancer where patients tend to delay treatment. The stock fell in after-hours trading despite the company beating on EPS.

But stepping back from the guidance revision, the operating engine is still humming. Trailing-twelve-month free cash flow sits at $1.158 billion, up 60% year over year. Operating margins are near 40%. The cabozantinib franchise grew 10% in the U.S. last quarter. And zanzalintinib - the next franchise molecule - has an FDA decision date of December 3.

The guidance cut is a pacing issue. The business is a cash machine that the market seems to be treating like it just broke.

The Cash Flow Is The Only Thing That Matters Here

Exelixis generated $1.158 billion in free cash flow over the past twelve months. That number grew 60% year over year while the company spent just $25 million on capital expenditures. For context, most pharma companies this size spend far more on facilities and equipment; Exelixis runs a lean, drug-revenue-focused operation where virtually every dollar of revenue converts to cash after R&D and SG&A.

The profit structure explains why. Gross margins sit above 96% - the standard for an oral oncology drug with no manufacturing complexity. Operating margins are 39.4%, and the free cash flow margin - the percentage of revenue that becomes distributable cash - is 38.1%. Return on invested capital is 37.7%. These are not numbers from a company in distress. They are numbers from a business that has already passed its biggest commercial risk.

On top of the cash generation, Exelixis ended June with approximately $1.4 billion in cash and marketable securities. The company announced a second $750 million share repurchase authorization in May, on top of the existing $750 million program, and burned through roughly $312 million of buybacks in Q2. That is $1.5 billion of capital commitments in a business that printed $1.16 billion of free cash flow last year.

Why The Guidance Cut Happened - And Why It Is Limited

Neuroendocrine tumors are indolent. They grow slowly, and oncologists tend to adopt a watch-and-wait approach until symptoms appear. That treatment pattern means cabozantinib's adoption in the NET space is ramping more gradually than Exelixis modeled. The company completed expanding its GI sales team in Q1 to push into community oncology, but NET simply does not have the urgency of renal cell carcinoma, where cabozantinib is the market leader.

This is a real headwind, but it is not a structural problem. The $50 million midpoint reduction comes from a single indication within a single product. Cabozantinib's global franchise revenue grew 13% year over year to $806 million in Q2. The core renal cell carcinoma franchise - which accounts for the bulk of cabozantinib revenue - remains intact and growing.

The guidance also narrowed to a $50 million range. That narrowing suggests management is less uncertain than before, not necessarily less confident.

Zanzalintinib: The Inflection That Is Four Months Away

This is where the 12-month picture gets interesting. The FDA has accepted Exelixis' new drug application for zanzalintinib in combination with atezolizumab for third-line-plus metastatic colorectal cancer, with a decision expected December 3. The application was built on the phase 3 STELLAR-303 trial, which met its primary endpoint in the overall population - showing a statistically significant overall survival improvement versus regorafenib, with a 20% reduction in the risk of death.

There is a complication worth stating plainly. STELLAR-303 has dual primary endpoints, and the second one - overall survival in patients without active liver metastases - missed statistical significance. The hazard ratio was 0.83 with a p-value of 0.1185, a positive trend that didn't clear the bar. Liver metastases matter in colorectal cancer because the liver's immunosuppressive environment can blunt immunotherapy effects, which is why Exelixis added the subpopulation endpoint after a rival trial by Merck and Eisai failed on the same question.

Two analyst groups - Leerink Partners and William Blair - argued on the day of the readout that FDA approval is still likely. The trial only needed one of the two primary endpoints to succeed, and the overall population clearly did. The more realistic risk is that the FDA could exclude the non-liver-metastases subgroup from the label, which would roughly halve the addressable patient population within the CRC indication. Leerink models zanzalintinib's unadjusted global peak in CRC at $1.3 billion, with the non-liver-metastases subgroup representing about half of that opportunity.

Even with a narrower label, approval would be a meaningful step toward the company's stated ambition of becoming a top-five solid tumor company by U.S. sales. And this would be only the first indication. Exelixis has six additional pivotal zanzalintinib trials running or planned across renal cell carcinoma, neuroendocrine tumors, early-stage CRC, meningioma, lung cancer, and prostate cancer. The STELLAR-304 readout in non-clear-cell renal cell carcinoma is expected later this year.

What The Market Is Getting Wrong

The stock is trading at 12.0 times trailing free cash flow, or roughly 21 times forward earnings. Neither multiple screams cheap. But the P/FCF of 12x is well below what the market typically assigns to profitable, growing pharma businesses with a pipeline option as large as zanzalintinib. The rolling annual return is up 51%, and the stock is sitting near its 52-week high of $57.57.

The market has rewarded the cash flow story so far - the stock is not falling on its face - but the after-hours sell-off on the guidance cut suggests the $50 million midpoint reduction triggered a re-pricing of near-term expectations. The concern that NET is underperforming is real, but it is already reflected in the narrowed, lower guidance. The question is whether the cabozantinib franchise and the buyback program can carry earnings through the next four months until the FDA zanzalintinib decision.

AInvest's aggregate rating sits at Hold, with a composite analysis score of 2.9 out of 5, despite fundamental and liquidity scores above 7. The consensus label reflects the uncertainty around zanzalintinib's label width and the guidance revision - not a view that the underlying cash generation has deteriorated.

The Setup

The next 12 months are binary on one dimension and linear on the rest. Zanzalintinib approval in December is the binary event. If it comes through - even with a narrower label than Exelixis hoped - the company crosses from single-franchise to dual-franchise territory. If the FDA rejects it or demands a clinical hold, the zanza pipeline option gets more expensive and the market will re-rate the entire pipeline downward.

The linear part is cabozantinib. Revenue growth has been steady at roughly 8-10% in the U.S., collaboration royalties are adding incremental income, and R&D expenses have actually declined year over year to $199.9 million in Q1 from $212.2 million. If cabo holds its current trajectory, the $2.325 billion midpoint for 2026 net product revenue is achievable. The company is already at $2.436 billion in total TTM revenue across all lines.

Target and timeframe: If zanzalintinib receives FDA approval in December - even with a partial label - and cabozantinib continues growing at the current pace, the business should print roughly $1.3 to $1.4 billion in free cash flow by the end of 2027. Applying a 13x free cash flow multiple - just above today's 12x but below the mid-to-high teens the market would assign to a confirmed dual-franchise business - implies a stock price in the $65 to $72 range over a 12-to-18 month window. That is a 15-27% return from current levels.

Tripwire: FDA rejection of the zanzalintinib NDA, or a clinical hold that pushes the decision well past December. Alternatively, if cabozantinib U.S. revenue growth drops below 5% in two consecutive quarters, the linear engine is losing steam and the thesis for continued buyback support weakens. In either case, the setup resets. Cut the position and reassess.

The market is still pricing a company that just cut its guidance. The cash flow says the business is stronger than the headline. The inflection sits four months away.